

Report Guide

WHAT'S INCLUDED IN THE REPORT?

DecisionDx-SCC provides validated information regarding:

- Risk of metastasis
- ART benefit
- Risk of local recurrence for NCCN HR patients

TEST RESULT AND RESULT DESCRIPTION

The test result for DecisionDx-SCC is reported as a classification of the gene expression profile result. Results and 3-year metastasis-free survival (MFS) rates are reported as:

- Class 1 - Low risk
- Class 2A - Higher risk
- Class 2B - Highest risk

CASTLE
BIOSCIENCES

Castle Biosciences, Inc. 100 S. Commons, Suite 245,
Pittsburgh, PA 15212

DecisionDx
-SCC

Castle ID: q0000-0 Page 1 of 2

FINAL REPORT

Patient:
Sex:
DOB:
Client:
Provider:

Tumor Site:
Specimen ID:
Collected:
Received:
Reported:

DecisionDx-SCC has been clinically validated in patients diagnosed with localized cutaneous squamous cell carcinoma (SCC) with at least one clinicopathologic risk factor to predict the following: (i) 3-year metastasis-free survival (MFS) (ii) Response to adjuvant radiation therapy (ART) in NCCN (2.2025) High-Risk (HR) or Very High-Risk (VHR) SCC with clear surgical margins; and (iii) local recurrence-free survival (LRFs) in NCCN HR SCC with no residual disease following Mohs surgery. As with all tests, these results should be evaluated within the context of the patient's other risk factors and overall clinical scenario.

DecisionDx-SCC Result

Class 2A

Class 2A signature is associated with a higher risk of metastasis within 3 years.

The DecisionDx-SCC test is validated to predict a patient's individual risk of metastasis (regional or distant) independent from all clinical or pathological risk factors and staging systems. The test was validated in two multi-center studies evaluating 897 patients, from 58 centers, diagnosed with localized SCC and one or more high-risk factors. **Three-year MFS for the entire population was 87.5%.** Patients without a metastatic event had a minimum of 3 years follow-up. Median time to metastasis was 0.73 years.

DecisionDx-SCC 3-Year Metastasis-Free Survival (MFS) Rates With BWH Staging and NCCN Risk Groups

DecisionDx-SCC result significantly improves risk stratification across BWH T-stages (T1, T2a, T2b) and NCCN HR and VHR groups.

DecisionDx-SCC	3-YEAR MFS	BWH			NCCN	
		T1	T2a	T2b	HR	VHR
Class 1	94.1%	97.3%	93.1%	81.1%	97.0%	85.4%
Class 2A	81.1%	88.7%	81.9%	63.6%	88.4%	72.2%
Class 2B	56.8%	66.7%	63.6%	41.7%	69.2%	50%
Overall	87.5%	93.7%	87.2%	67.7%	93.5%	76.0%

BWH Risk Factors: Tumor size ≥ 2 cm, perineural invasion (PNI) ≥ 0.1 mm, poor differentiation, invasion beyond subcutaneous fat; T1 (0 risk factors), T2a (1 risk factor), T2b (2-3 risk factors).

NCCN HR Factors: Tumor size > 2 cm - ≤ 4 cm on trunk or extremities, any size on the head, neck, hands, feet, pretibial and anogenital area, borders poorly defined, immunosuppression, rapidly growing tumor, site of prior radiation therapy or chronic inflammation, neurological symptoms, 2-6 mm depth and no invasion beyond subcutaneous fat, select histologic subtypes.

NCCN VHR Factors: Tumor size > 4 cm (any location), poorly differentiated, desmoplastic SCC, > 6 mm or invasion beyond subcutaneous fat, perineural invasion (PNI) ≥ 0.1 mm, lymphatic or vascular involvement.

VALIDATION AND SUPPORTING DATA

DecisionDx-SCC is validated to predict individual risk of metastasis within 3 years of diagnosis for patients with SCC and one or more risk factors:

- Clinically validated in 897 patients in two, independent, multi-center studies with 3-year outcomes
- Strongest independent predictor of SCC metastasis
- Test result adds significant information for SCC management

3-YEAR MFS RATE OF DECISIONDX-SCC TEST RESULTS IN CONJUNCTION WITH BWH STAGING AND NCCN RISK GROUPS

DecisionDx-SCC is an independent predictor of metastatic risk and can be combined with BWH staging or NCCN risk groups. Integration of DecisionDx-SCC with BWH or NCCN significantly improves the accuracy of risk stratification allowing more personalized treatment decisions.

RESPONSE TO ADJUVANT RADIATION THERAPY (ART)

Based on two independent studies, DecisionDx-SCC predicts which patients may benefit from ART, based on the Class result. DecisionDx-SCC informs ART consideration alongside other clinical risk factors and the overall clinical scenario.

- Class 1- No clinically discernable benefit from ART
- Class 2A - May benefit from ART
- Class 2B - Likely to benefit from ART

ABOUT THE TEST

- DecisionDx-SCC is a gene expression profile test consisting of 40 genes (34 discriminant and 6 control)
- RT-PCR technology is used to measure gene expression levels of the discriminant genes which are normalized to the control genes



Castle Biosciences, Inc. 100 S. Commons, Suite 245,
Pittsburgh, PA 15212



Castle ID: q0000-0 Page 2 of 2

Response to Adjuvant Radiation Therapy (ART)

Class 2A

Potential benefit from ART on metastatic disease progression when considered in context of other high-risk factors.*

NCCN (2.2025) recommends consideration of ART in patients with localized NCCN HR or VHR SCC, clear surgical margins and a high risk for regional or distant metastasis. The performance of DecisionDx-SCC in predicting response to ART has been validated in two independent multi-center studies in patients diagnosed with localized invasive SCC and meeting NCCN HR or VHR criteria (Arron et al, Ruiz et al; n=1,320). These studies represent the two largest studies conducted to date evaluating the benefit of ART in patients with high-risk SCC.

*Class 2A result is an additional, independent high-risk factor that indicates an increased risk for metastasis that is similar to other factors including PNI (>0.1mm), poor differentiation, invasion beyond subcutaneous fat, and immunosuppression.

Scan the QR code for additional information regarding DecisionDx-SCC ART guidance.



DecisionDx-SCC 3-Year Local Recurrence-Free Survival (LRFS) Rates (%) for Mohs-treated NCCN HR Patients

Class 2A

Class 2A signature is associated with a higher risk of local recurrence within 3 years.

In a multi-center validation study of 414 patients diagnosed with NCCN HR SCC who underwent definitive Mohs surgery with no residual disease (R0), DecisionDx-SCC was shown to provide risk stratification independent of NCCN and BWH risk systems. This study had an overall local recurrence-free survival (LRFS) rate of 91.8%. A Class 1, Class 2A and Class 2B test result yielded a LRFS rate of 95.3%, 85.5% and 71.4%, respectively. Please refer to page 1 of this report for a full list of NCCN HR factors.

About the Test

The DecisionDx-SCC test is a qRT-PCR assay of 6 control and 34 discriminant genes (40 in total) that uses a neural network algorithm comprised of two gene expression signatures to classify patients into risk categories. The algorithmic score from both signatures is converted to results reflecting risk classification. DecisionDx-SCC is indicated for patients with cutaneous squamous cell carcinoma (SCC) and one or more high-risk factors (see Test Requisition Form). The test predicts individual metastatic risk, response to ART, and risk of local recurrence to help inform risk appropriate management.

The 34 discriminant genes are: ACSBG1, ALOX12, APOBEC3G, ATP6V0E2, BBC3, BHLHB9, CEP76, DUXAP9, GTPBP2, HADC3, ID2, LCE2B, LIME1, LOC100287896, LOC101927502, MMP10, MRC1, MSANTD4, NFASC, NFIC, PDN, PI3, PLS3, RCHY1, RNF135, RPP38, RUNX3, SLC1A3, SPPI, TAF6L, TFAP2B, ZNF48, ZNF496 and ZNF839. Six control genes consist of BAG6, FXR1, KMT2C, KMT2D, MDM2, MDM4

For additional information about the development, validation and clinical use of the DecisionDx-SCC test, including references, scan the QR code.



Digitally signed by Castle Lab Director, PhD, HCLD[®]
Date: 2023.12.26 11:51:39 GMT-7'00'

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director



This test was developed and its performance characteristics determined by Castle Biosciences Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Castle Biosciences, Inc., CLIA# 39C210302

100 S. Commons, Suite 245, Pittsburgh, PA 15212
Tel: 866-788-9007 Fax: 878-213-3022

Version v3.0 06/25 ©2025

3-YEAR LOCAL RECURRENCE FREE SURVIVAL RATES IN MOHS-TREATED NCCN HR PATIENTS

DecisionDx-SCC is shown to be a significant predictor of local recurrence, adding prognostic value to support tailored post-surgery management decisions. Results and 3-year Local recurrence free survival (LRFS) rates are reported as:

- Class 1 - Low risk - 95.3% LRFS
- Class 2A - Higher risk - 85.5% LRFS
- Class 2B - Highest risk - 71.4% LRFS

Additional information

For additional information about the development and validation of the DecisionDx-SCC test and references, scan the QR code below.

